AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00654667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, no active drug, take 5 capsules by mouth daily for one month
Trial: NCT02249338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01075243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03593902
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A medication used as chemotherapy and to suppress the immune system
Trial: NCT00334880
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00822614
Drug: Fentanyl TAIFUN
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhalation of Fentanyl via TAIFUN inhaler
Trial: NCT00822614
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current optimized BTP treatment
Trial: NCT03600909
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
Trial: NCT00545740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD orally
Trial: NCT01540110
Drug: Neoadjuvant Docetaxel and Cyclophosphamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)
Trial: NCT00641979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00554424
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
Trial: NCT02765100
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg twice a day
Trial: NCT00808405
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo taken orally three times daily for 5 days.
Trial: NCT03605667
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matching placebo will be given daily for up to 48 weeks
Trial: NCT04686461
Drug: Nigella sativa seeds extract containing ointment intervention
RxNorm normalized name: Nigella sativa seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
Trial: NCT00980187
Drug: Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
Trial: NCT04653506
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
Trial: NCT05066802
Drug: neoadjuvant modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
Trial: NCT02111421
Drug: Dexmetomidine 02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
Trial: NCT03926286
Drug: FMP-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
Trial: NCT03636555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
Trial: NCT00149968
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
Trial: NCT04392960
Drug: [18F]Florbetaben
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Trial: NCT01900249
Drug: R348 Ophthalmic Solution, 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
Trial: NCT01900249
Drug: R348 Ophthalmic Solution, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
Trial: NCT01900249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
Trial: NCT02114528
Drug: Antiarrhythmic Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
Trial: NCT02291094
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Trial: NCT00792922
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of community coverage rate
Trial: NCT02433626
Drug: COTI2
RxNorm normalized name: Coti2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COTI-2 is a third generation thiosemicarbazone.
Trial: NCT00792922
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
Trial: NCT03389659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 5 pills po. qd continue to disease progression
Trial: NCT04587505
Drug: Continuous intravenous analgesia
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Trial: NCT02189772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive drug
Trial: NCT00388128
Drug: Caffeine 6mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
Trial: NCT00584948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
Trial: NCT02620631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
Trial: NCT04312061
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo tablet given 1 hour before LNG-IUD insertion
Trial: NCT01988649
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of normal saline intranasally.
Trial: NCT02914158
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01077986
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
Trial: NCT03953001
Drug: 2% Lidocaine with 1:50,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Dental anesthetic infiltration
Trial: NCT02079506
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01673529
Drug: SB705498
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
Trial: NCT01159275
Drug: Aluvia and Generic LPV/r (pharmacokinetics)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
Trial: NCT03968588
Drug: Tacrolimus(reduced), Mycophenolate mofetil(standard)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
Trial: NCT03968588
Drug: Tacrolimus(standard), Mycophenolate mofetil(reduced)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
Trial: NCT02014831
Drug: TIP
RxNorm normalized name: Q-Tips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Trial: NCT00470223
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00470223
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00596336
Drug: influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trispecific influenza vaccine 0.5 ml subcutaneously
Trial: NCT01673529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match SB705498 will be used in both Part A and Part B of the study.
Trial: NCT02670109
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80mg/kg, IV, in 2 hours, during two days -2, -3
Trial: NCT00409838
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months
Trial: NCT00409838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
Trial: NCT02055976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
Trial: NCT02055976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q14D SC for 16 week
Trial: NCT00409838
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, oral, 15 mg weekly to be adjusted according to patient condition
Trial: NCT00972049
Drug: AZD2516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered once orally. Specific dose depends on dose panel.
Trial: NCT00972049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered once orally
Trial: NCT00186849
Drug: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT05021666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00633477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
Trial: NCT02022059
Drug: Group B placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
Trial: NCT00100698
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneously once a day, 18 months
Trial: NCT01426412
Drug: LY3015014 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV over 30-90 minutes
Trial: NCT04337879
Drug: AL2846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
Trial: NCT04337879
Drug: Calcium folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
Trial: NCT00313742
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01426412
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV only over 30-90 minutes
Trial: NCT01439789
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Trial: NCT01439789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Trial: NCT01766050
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03895515
Drug: Fiasp®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
Trial: NCT03452397
Drug: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
Trial: NCT04239001
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
Trial: NCT03525444
Drug: VX-445/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Trial: NCT03525444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Trial: NCT03452397
Drug: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
Trial: NCT03744910
Drug: Physiologic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT02973100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03818100
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
Trial: NCT02942862
Drug: Orcein staining
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic value of venous emboli detected by orcein staining
Trial: NCT03037892
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group 3 patient will receive only Remifentanil in the same doses as given in group
Trial: NCT02892214
Drug: estriol cream (ovestin)
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00971724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, once daily, for 15 days
Trial: NCT00971724
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02814838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT03767452
Drug: Xiaflex® 0.58 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mL injections.
Trial: NCT02229721
Drug: Syntocinon Nasalspray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
Trial: NCT01751269
Drug: RPX7009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Trial: NCT01751269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
Trial: NCT02229721
Drug: Placebo Nasalspray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
Trial: NCT00220519
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00704314
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg Simvastatin daily for 8 weeks
Trial: NCT00704314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was identical in appearance and was provided by the same manufacturer
Trial: NCT00662519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
Trial: NCT04846829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
Trial: NCT02161770
Drug: AZD9291 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
Trial: NCT00517673
Drug: GSK945237
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02809989
Drug: Ovaleap®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births).